ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0715

Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France

(0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0595

Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0683

Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0092

SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging

(0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0463

Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0464

Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0214

Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: Abstract Number: 0615

Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0709

Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0685

Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0678

Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0055

TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis

(0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0545

Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0452

Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0434

The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].